TelAviv:PLX

Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

Retrieved on: 
星期五, 五月 3, 2024
Protalix BioTherapeutics, Calendar, EDT, Webcast

CARMIEL, Israel, May 3, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.

Key Points: 
  • Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments.
  • The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
  • Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software.
  • A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

Retrieved on: 
星期四, 三月 7, 2024
EDT, Protalix BioTherapeutics, Webcast

CARMIEL, Israel, March 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2023 and provide a business update on Thursday, March 14, 2024.

Key Points: 
  • Company to host conference call and webcast at 8:30 a.m. EDT
    CARMIEL, Israel, March 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2023 and provide a business update on Thursday, March 14, 2024.
  • Management will host a conference call with investors to discuss the financial results and provide a business update.

Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference

Retrieved on: 
星期五, 二月 23, 2024
BIO, Conference, Protalix BioTherapeutics

CARMIEL, Israel, Feb. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City.

Key Points: 
  • Corporate presentation scheduled for Monday, February 26, 2024 at 1:00 PM ET
    CARMIEL, Israel, Feb. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced that it will attend and present at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 at the New York Marriott Marquis in New York City.
  • Management is scheduled to give a corporate overview at the BIO CEO & Investor Conference on Monday, February 26, 2024 at 1:00 PM ET at the Plymouth Room and will be available to participate in one-on-one partnering meetings with registered investors and other conference attendees.
  • Following the presentation, a copy will be available under the Event Calendar tab in the Investors section of the Company's website.
  • Conference attendees that would like to schedule a meeting with the Company's management are encouraged to register through the BIO CEO attendee portal.

Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023

Retrieved on: 
星期一, 十月 30, 2023
EST, Protalix BioTherapeutics, Calendar, Webcast, Broadcasting

CARMIEL, Israel, Oct. 30, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the third quarter ended September 30, 2023 and provide a business update on Monday, November 6, 2023.

Key Points: 
  • Company to host conference call and webcast at 8:30 a.m. EST
    CARMIEL, Israel, Oct. 30, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the third quarter ended September 30, 2023 and provide a business update on Monday, November 6, 2023.
  • Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments.
  • The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.
  • A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel

Retrieved on: 
星期一, 十月 9, 2023
Friends, Fine chemical, Protalix BioTherapeutics

CARMIEL, Israel, Oct. 9, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today issued the following statement by Dror Bashan, Protalix's President and Chief Executive Officer, regarding the current security situation in Israel.

Key Points: 
  • CARMIEL, Israel, Oct. 9, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today issued the following statement by Dror Bashan, Protalix's President and Chief Executive Officer, regarding the current security situation in Israel.
  • "The Protalix family is horrified by the unconscionable events in Israel over the past weekend which are currently ongoing and the scope of which is yet to be determined.
  • On a personal level, we are heartbroken and pray for the victims as well as their families, friends and other loved ones.
  • At Protalix, we are dedicated to helping our own families, friends and colleagues cope with this devastating situation and to provide them with any support they need.

Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
星期三, 九月 6, 2023
Bashan, Lotte New York Palace Hotel, Conference, NYSE, Protalix BioTherapeutics, EDT, Fine chemical, Security (finance), Hotel

CARMIEL, Israel, Sept. 6, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present on Wednesday, September 13, 2023 at 3:00 p.m. Eastern Daylight Time (EDT) at the H.C. Wainwright 25th Annual Global Investment Conference.

Key Points: 
  • CARMIEL, Israel, Sept. 6, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present on Wednesday, September 13, 2023 at 3:00 p.m. Eastern Daylight Time (EDT) at the H.C. Wainwright 25th Annual Global Investment Conference.
  • The conference is being held on September 11-13, 2023 at the Lotte New York Palace Hotel, New York City, NY.
  • Mr. Bashan will provide a live corporate overview at the conference, and will participate in one-on-one meetings with investors who are registered to attend the conference.

Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results

Retrieved on: 
星期一, 八月 7, 2023
Protalix BioTherapeutics, Medsafe, European Medicines Agency, Tax, MD, Patient, European, Fabry disease, BLA, NYSE, Calendar, Gout, Half-life, Pharmacokinetics, Research, EMA, Russell, FIH, Growth, FDA, PEGylation, Biologics license application, Safety, Civil service commission, Health, Baylor University Medical Center, Israel Innovation Authority, FASN, Webcast, MAA, HDEC, European Commission, KOL, Clinical trial, EDT, Marketing, ERT, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Vaccine, Pharmaceutical industry, Drug, Life insurance, Online shopping, EU, Fabry, Chiesi Farmaceutici

CARMIEL, Israel, Aug. 7, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the second quarter ended June 30, 2023 and provided a business update on recent regulatory, clinical and corporate developments.

Key Points: 
  • "2023 has been a transformational year for Protalix thus far," said Dror Bashan, Protalix's President and Chief Executive Officer.
  • On May 5, 2023, the European Commission (EC) granted marketing authorization to Elfabrio (pegunigalsidase alfa) in the European Union.
  • On June 26, 2023, the Company was included in the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution.
  • Financial expenses, net were $0.8 million for the three months ended June 30, 2023, compared to financial income, net of $0.2 million for the three months ended June 30, 2022.

Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023

Retrieved on: 
星期一, 七月 31, 2023
Webcast, Calendar, NYSE, Protalix BioTherapeutics, EDT

CARMIEL, Israel, July 31, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the second quarter ended June 30, 2023 and provide a business update on Monday, August 7, 2023.

Key Points: 
  • Company to host conference call and webcast at 8:30 a.m. EDT
    CARMIEL, Israel, July 31, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the second quarter ended June 30, 2023 and provide a business update on Monday, August 7, 2023.
  • Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments at 8:30 a.m. Eastern Daylight Time (EDT).
  • The Call me™ feature, which avoids having to wait for an operator, may be accessed at the following link: https://tinyurl.com/2v682k5m .
  • A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

Protalix BioTherapeutics to Announce First Quarter 2023 Financial and Business Results on May 4, 2023

Retrieved on: 
星期四, 四月 27, 2023
Webcast, Calendar, NYSE, Protalix BioTherapeutics, EDT

CARMIEL, Israel, April 27, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the first quarter ended March 31, 2023 and provide a business update on Thursday, May 4, 2023.

Key Points: 
  • Company to host conference call and webcast at 8:30 a.m. EDT
    CARMIEL, Israel, April 27, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will release its financial results for the first quarter ended March 31, 2023 and provide a business update on Thursday, May 4, 2023.
  • Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments at 8:30 a.m. Eastern Daylight Time (EDT).
  • The conference will be webcast live from the Company's website and will be available via the following links:
    Please access the websites at least 15 minutes ahead of the conference call to register, download and install any necessary audio software.
  • The conference call will be available for replay for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

Protalix BioTherapeutics to Participate in the 19th Annual WORLDSymposium™ 2023

Retrieved on: 
星期二, 二月 21, 2023
NYSE, TASE, Protalix BioTherapeutics, PEGylation, Fabry disease, Abstract, Hilton Orlando Lake Buena Vista, Vaccine, Chiesi Farmaceutici

CARMIEL, Israel, Feb. 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will participating in the 19th Annual WORLDSymposium™ 2023, taking place February 22–26, 2023 at the Hilton Orlando in Orlando, Florida.

Key Points: 
  • CARMIEL, Israel, Feb. 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it will participating in the 19th Annual WORLDSymposium™ 2023, taking place February 22–26, 2023 at the Hilton Orlando in Orlando, Florida.
  • The Company will be hosting an informational booth at the symposium.
  • PRX–102 is a purposefully-designed, long-acting recombinant, PEGylated, cross–linked α–galactosidase–A investigational product candidate under development for the potential treatment of Fabry disease.
  • The Company will make Chiesi's PRX–102 presentations and related abstracts on its website under the Presentation tab in the Investors section: https://protalixbiotherapeutics.gcs-web.com/presentations .